Last reviewed · How we verify
Florbetaben (BAY94-9172)
Florbetaben (BAY94-9172) is a PET imaging agent / amyloid tracer Small molecule drug developed by Life Molecular Imaging SA. It is currently in Phase 3 development for Detection of amyloid-beta plaques in patients with cognitive impairment or suspected Alzheimer's disease.
Florbetaben is a fluorine-18 labeled imaging agent that binds to amyloid-beta plaques in the brain for positron emission tomography (PET) detection.
Florbetaben is a fluorine-18 labeled imaging agent that binds to amyloid-beta plaques in the brain for positron emission tomography (PET) detection. Used for Detection of amyloid-beta plaques in patients with cognitive impairment or suspected Alzheimer's disease.
At a glance
| Generic name | Florbetaben (BAY94-9172) |
|---|---|
| Sponsor | Life Molecular Imaging SA |
| Drug class | PET imaging agent / amyloid tracer |
| Target | Amyloid-beta plaques |
| Modality | Small molecule |
| Therapeutic area | Neurology / Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
Florbetaben is a PET tracer designed to visualize amyloid-beta accumulation in the brain by binding to amyloid plaques. The fluorine-18 radiolabel enables detection via PET imaging, allowing clinicians to assess amyloid burden in patients with cognitive impairment or suspected Alzheimer's disease. This diagnostic tool helps identify amyloid pathology that correlates with neurodegenerative disease progression.
Approved indications
- Detection of amyloid-beta plaques in patients with cognitive impairment or suspected Alzheimer's disease
Common side effects
- Injection site reactions
- Headache
- Dizziness
Key clinical trials
- Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172 (NA)
- Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology (PHASE3)
- Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers (PHASE2)
- Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients (PHASE1)
- Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Florbetaben (BAY94-9172) CI brief — competitive landscape report
- Florbetaben (BAY94-9172) updates RSS · CI watch RSS
- Life Molecular Imaging SA portfolio CI
Frequently asked questions about Florbetaben (BAY94-9172)
What is Florbetaben (BAY94-9172)?
How does Florbetaben (BAY94-9172) work?
What is Florbetaben (BAY94-9172) used for?
Who makes Florbetaben (BAY94-9172)?
What drug class is Florbetaben (BAY94-9172) in?
What development phase is Florbetaben (BAY94-9172) in?
What are the side effects of Florbetaben (BAY94-9172)?
What does Florbetaben (BAY94-9172) target?
Related
- Drug class: All PET imaging agent / amyloid tracer drugs
- Target: All drugs targeting Amyloid-beta plaques
- Manufacturer: Life Molecular Imaging SA — full pipeline
- Therapeutic area: All drugs in Neurology / Diagnostic Imaging
- Indication: Drugs for Detection of amyloid-beta plaques in patients with cognitive impairment or suspected Alzheimer's disease
- Compare: Florbetaben (BAY94-9172) vs similar drugs
- Pricing: Florbetaben (BAY94-9172) cost, discount & access